Apalutamide improves overall survival
Apalutamide added to ongoing androgen deprivation therapy (ADT) significantly improves overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Earlier results from the SPARTAN study had showed that apalutamide could improve metastasis-free survival by two years but OS data was immature.
This follow-up paper published …